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Background: Dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin 
(mTOR) inhibition offers an attractive therapeutic strategy in anaplastic large cell lymphoma 
depending on oncogenic nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) signaling. 
We tested the efficacy of a novel dual PI3K/mTOR inhibitor, NVP-BGT226 (BGT226), in 
two anaplastic large cell lymphoma cell lines in vitro and in vivo and performed an early 
response evaluation with positron emission tomography (PET) imaging using the standard 
tracer, 2-deoxy-2-[18F]fluoro-D-glucose (FDG) and the thymidine analog, 3′-deoxy-3′-[18F]
fluorothymidine (FLT).
Methods: The biological effects of BGT226 were determined in vitro in the NPM-ALK positive 
cell lines SU-DHL-1 and Karpas299 by 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide assay, propidium iodide staining, and biochemical analysis of PI3K and mTOR down-
stream signaling. FDG-PET and FLT-PET were performed in immunodeficient mice bearing 
either SU-DHL-1 or Karpas299 xenografts at baseline and 7 days after initiation of treatment 
with BGT226. Lymphomas were removed for immunohistochemical analysis of proliferation 
and apoptosis to correlate PET findings with in vivo treatment effects.
Results: SU-DHL-1 cells showed sensitivity to BGT226 in vitro, with cell cycle arrest in G0/G1 
phase and an IC
50
 in the low nanomolar range, in contrast with Karpas299 cells, which were 
mainly resistant to BGT226. In vivo, both FDG-PET and FLT-PET discriminated sensitive from 
resistant lymphoma, as indicated by a significant reduction of tumor-to-background ratios on 
day 7 in treated SU-DHL-1 lymphoma-bearing animals compared with the control group, but 
not in animals with Karpas299 xenografts. Imaging results correlated with a marked decrease in 
the proliferation marker Ki67, and a slight increase in the apoptotic marker, cleaved caspase 3, 
as revealed by immunostaining of explanted lymphoma tissue.
Conclusion: Dual PI3K/mTOR inhibition using BGT226 is effective in ALK-positive ana-
plastic large cell lymphoma and can be monitored with both FDG-PET and FLT-PET early on 
in the course of therapy.
Keywords: lymphoma, phosphatidylinositol-3-kinase, mammalian target of rapamycin, inhibi-
tion, positron emission tomography
Introduction
Anaplastic large cell lymphoma (ALCL) is an aggressive subtype of non-Hodgkin 
lymphoma originating from the T/null lineage. Initially it is a curable disease, but 
refractory and relapsed patients have a much worse prognosis. Therefore, there is an 
urgent need for new therapies in this disease.
The majority of ALCL is associated with the t(2;5)(p23;q53) chromo-
somal translocation which results in expression of the oncogenic fusion protein 
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nucleophosmin-anaplastic lymphoma kinase (NPM-ALK).1 
NPM-ALK has a constitutive active tyrosine kinase function 
leading to activation of several signal transduction pathways, of 
which the phosphatidylinositol-3-kinase (PI3K)/Akt pathway is 
of particular interest in tumor biology.2,3 It is well established that 
oncogenic activation of the PI3K/Akt pathway contributes to a 
malignant phenotype in both solid and hematological malignan-
cies due to its effects on various cellular functions, including 
cell survival, growth, proliferation, angiogenesis, metabolism, 
and migration.4 Accordingly, inhibition of this signaling cascade 
has been a focus in developmental therapeutics. One important 
component of the PI3K/Akt signaling network in relation 
to carcinogenesis is the enzyme target mammalian target of 
rapamycin (mTOR), which is present in at least two distinct cel-
lular complexes termed mTOR-raptor (mTORC1) and mTOR-
rictor (mTORC2), respectively.5 Briefly, mTORC2 activates 
Akt by phosphorylation, whereas mTORC1 promotes mRNA 
translation of multiple proteins, including Mcl-1 (a prosurvival 
factor), cyclin D3 (a cell cycle regulator), the proangiogenic 
vascular endothelial growth factor, and glucose transporter 1, 
as well as proteins involved in lipid and protein metabolism 
via its substrates, ie, eukaryotic initiating factor-4e binding 
protein 1 and S6 kinase (S6K). Importantly, S6K exerts strong 
negative feedback control on the activity of PI3K. Consequently, 
inhibition of mTORC1 releases the S6K-mediated negative 
feedback loop, resulting in a paradoxical increase of PI3K and 
Akt activity.5 Therefore, there is legitimate concern that the effi-
cacy of selective mTORC1 inhibitors, which include rapamycin 
and its analogs (rapalogs), eg, everolimus, is limited. This has 
already been shown in clinical trials.6 Concomitant PI3K and 
mTOR inhibition, however, offers the theoretical advantage 
of effective abrogation of the PI3K/Akt/mTOR pathway.6 In a 
large in vitro study, the two dual PI3K/mTOR inhibitors, NVP-
BEZ235 (BEZ235) and NVP-BGT226 (BGT226), showed 
efficacy in a broad set of hematological malignancies, including 
aggressive lymphoma, multiple myeloma, and acute leukemia.7 
However, there was considerable variability in the response to 
each drug within any individual lymphoma histology. In fact, 
the heterogeneity in drug response within a particular histology 
was generally comparable with that observed between different 
histologies. These findings support the demand for predictive 
markers enabling clinicians to evaluate treatment response early 
in the course of therapy, thus preventing unnecessary toxicity and 
costs in the event of refractory disease. In addition, these tools 
would help to accelerate evaluation of new drugs in the preclini-
cal and clinical setting.
Imaging modalities provide an attractive option. Positron 
emission tomography (PET) with the glucose analog 
2-deoxy-2-[18F]fluoro-D-glucose (FDG) has significant 
value for diagnosis, staging, and post-treatment assessment 
in aggressive lymphoma.8 However, clinical studies regard-
ing interim FDG-PET to assess early treatment response, 
ie, after two or four cycles of chemotherapy, have yielded 
mixed results.9–11 One important limitation of FDG is its 
nonspecific uptake in inflammatory lesions, leading to 
false-positive results.12 In contrast with FDG, which tracks 
general cellular metabolism, 3′-deoxy-3′-[18F]fluorothymi-
dine (FLT) has been developed for visualizing tumor cell 
proliferation.13 After uptake by nucleoside transporters, FLT 
is phosphorylated by thymidine kinase 1, a cytosolic enzyme 
which represents the rate-limiting step for retention of FLT 
within the cell. Thymidine kinase 1 expression and activity is 
closely related to the S-phase of the cell cycle, making FLT 
an excellent surrogate marker for proliferation.14,15 We have 
previously shown that FLT is suitable for prediction of the 
early response to chemotherapy in aggressive lymphoma,16,17 
and that it offers advantages over the standard tracer FDG 
in monitoring early response to targeted and dose-dependent 
chemotherapy.18,19
The objective of this study was to assess the efficacy of 
BGT226, a novel dual PI3K/mTOR inhibitor, in a xenograft 
mouse model of human ALCL and to monitor the response 
to treatment noninvasively using FDG-PET and FLT-PET 
imaging.
Materials and methods
cell lines and animal model
SU-DHL-1 and Karpas299 cells, derived from human ALCL 
harboring the t(2;5) translocation, were obtained from the 
German Collection of Microorganisms and Cell Cultures. 
All cells were cultured in Roswell Park Memorial Institute 
1640 medium containing 10% fetal bovine serum, 1 mM 
L-glutamine, and 1% penicillin/streptomycin (Life Tech-
nologies, Carlsbad, CA, USA). Female immunodeficient 
mice (CB-17 SCID) aged 6–8 weeks were obtained from the 
Charles River Laboratories (Wilmington, MA, USA). For 
induction of tumors, 10×106 SU-DHL-1 or 5×106 Karpas299 
cells suspended in 100 µL of sterile phosphate-buffered saline 
were injected subcutaneously into the right shoulder region. 
All animal experiments were authorized by the regional gov-
ernment agency (Regierung von Oberbayern).
inhibitor
BGT226 (a dual PI3K/mTOR inhibitor) was provided by 
Novartis (Basel, Switzerland). The inhibitor was solubilized 
in 0.01% HCl to 1 µM stock solution and stored at −20°C. 
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The primary solution was diluted to 0–100 nM with Roswell 
Park Memorial Institute 1640 medium for cell culture.
MTT assay
MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide) assays were performed according to the manufac-
turer’s instructions (Promega Corporation, Madison, WI, 
USA). Briefly, 1×104 SU-DHL-1 or Karpas299 cells per 
well (96-well plate) were incubated at 37°C with different 
concentrations of BGT226 for 24 and 48 hours. Next, 20 µL 
of MTT dilution in phosphate-buffered saline were added to 
each well, and the cells were incubated for 90 minutes. Absor-
bance was measured at 570 nm using a Bio-Tek EL×800™ 
Series universal microplate reader (Progen Scientific, Kuala 
Lumpur, Malaysia).
Flow cytometry
Lymphoma cells (5×105 per well in 12-well plates) were 
incubated with different concentrations of BGT226 at 37°C. 
After 24 and 48 hours, the cells were centrifuged (1,700 U per 
minute for 7 minutes) and stored in 3 mL of ethanol (70%) 
at −20°C. On the day of analysis, cells were centrifuged and 
resuspended in 300 µL of phosphate-buffered saline. After 
RNA digestion by ribonuclease A (95%, Sigma-Aldrich, 
St Louis, MO, USA), propidium iodide (Sigma-Aldrich) 
was added at a dilution of 1:500. Cells were incubated 
for 30 minutes at 37°C and analyzed (Beckman Coulter, 
 Fullerton, CA, USA).
immunoblotting
Cells were incubated with different concentrations of 
BGT226 at 37°C. After 6 hours, cells were washed, pelleted, 
and stored at −80°C. After lysis, the protein concentration 
was determined using protein assay dye reagent (Bio-Rad 
Laboratories, Inc., GmbH, Munich, Germany) with bovine 
serum albumin as standard. For immunoblotting, 50 µg of 
protein per lane was separated on 7.5% gradient ready-
made sodium dodecyl sulfate gel (Bio-Rad Laboratories, 
Inc.) and transferred to a polyvinylidene difluoride mem-
brane (EMD Millipore Corporation, Billerica, MA, USA). 
Primary antibodies (AKT or p-AKT, p70S6K or p-p70S6K; 
all from Cell Signaling Technology Inc., Danvers, MA, 
USA) were diluted 1:200 into blocking buffer and incu-
bated overnight at 4°C, and then washed and incubated 
with secondary antibody. Blots were developed using a 
Pierce Fast Western blot kit (Thermo Fisher Scientific, 
Waltham, MA, USA) and exposed to film (Thermo Fisher 
Scientific).
Tumor volume and therapeutic regimens
Tumor diameters were measured daily with a shifting caliper 
by the same person followed by tumor volume calculation 
using the formula (length × [width]2)/2. When xenotrans-
plants reached a size of approximately 300 mm³ (day 0), 
ie, about 4 weeks after injection of SU-DHL-1 cells and one 
week after injection of Karpas299 cells, the animals were 
treated with BGT226 (7.5 mg/kg orally) for 4 consecutive 
days. Treatment was then stopped for 3 days and resumed 
on day 7 (ie, “4 days on, 3 days off ”). The control group 
received 0.01% HCl only.
PeT imaging
FLT and FDG were synthesized as previously described,20 
and were obtained from the Radiopharmacy Unit of the 
Technische Universität München. Imaging was performed 
using a micro PET system (Inveon™, Siemens Preclinical 
Solutions, Knoxville, TN, USA). FLT or FDG was admin-
istered via tail vein injection (100 µL) at an activity dose 
of 5–10 MBq per mouse. Accumulation of radiotracer in 
the tumor was allowed for 60 minutes. The mice were then 
imaged using a 15-minute static acquisition.
PeT data analysis
Tumor-to-background ratios (TBRs) were calculated for 
semiquantitative assessment of tracer accumulation in the 
tumor. Circular three-dimensional regions of interest were 
placed manually in the area with the highest tumor activity. 
The diameters did not cover the entire tumor volume to 
avoid partial volume effects. For determination of back-
ground activity, two three-dimensional regions of interest 
were placed in the spinal muscle at the level of the kidneys. 
Corresponding TBR, mean
tumor
/mean
muscle
, were calculated.
histological and immunohistochemical 
analysis
Formalin-fixed, paraffin-embedded sections (5 µm) of 
resected tumor tissue were dewaxed, rehydrated, and micro-
waved for 30 minutes in 0.01 M citrate buffer (pH 6.0) 
containing 0.1% Tween 20. Sections were washed in Tris-
buffered saline (pH 7.6) containing 5% fetal calf serum 
(Life Technologies, Carlsbad, CA, USA) for 20 minutes. The 
primary antibodies used were: anti-Ki67 antigen antibody 
solution (MIB-1, M7240, Dako; 1:75 diluted with Antibody 
Diluent [Dako ChemMate; Dako, Glostrup, Denmark]) 
and anti-cleaved caspase-3 rabbit monoclonal antibody 
solution (Asp175, Cell Signaling Technology Inc.). The 
remainder of the procedure was performed on an automated 
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immunostainer (Discovery XT, Ventana Medical Systems Inc., 
Oro Valley, AZ, USA). Diaminobenzidine (Ventana Medical 
Systems Inc.) liquid served as the chromogen.
statistical analysis
Statistical analyses were performed using the statistical 
function of Excel 2007 (Microsoft, Redmond, WA, USA) or 
GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, 
USA). A P-value ,0.05 as assessed by two-tailed Student’s 
t-test was considered to be statistically significant.
Results
sU-Dhl-1 cell line is sensitive  
to BgT226 in vitro
We first investigated the in vitro efficacy of dual PI3K/mTOR 
inhibition with BGT226 in a cell line-based lymphoma 
model comprising two ALCL cell lines, ie, SU-DHL-1 and 
Karpas299, both of which depend on constitutive NPM-
ALK signalling18 and therefore seemed to be suitable for 
testing BGT226. Viability of SU-DHL-1 cells was impaired 
by BGT226 in a dose-dependent and to some degree time-
dependent manner, as shown by MTT assay, with a maximum 
effect at the 100 nM dose level and an IC
50
 of less than 10 
nM (Figure 1A). Cell cycle analysis using propidium iodide 
staining showed induction of cell cycle arrest, as demonstrated 
by a significant decrease of the S phase fraction and a marked 
increase of the G0/G1 fraction, as well as proapoptotic effects 
at higher dose levels, as indicated by an increase of the subG1 
fraction (Figure 1B). At the protein level, expression of phos-
phorylated p70S6K, one of the downstream targets of mTOR,6 
was virtually undetectable at the 10 nM dose level after 6 hours 
of incubation with BGT226. In addition, the phosphorylated 
form of the PI3K downstream signaling molecule Akt6 was 
reduced in a dose-dependent manner (Figure 1C). Thus, SU-
DHL-1 is an NPM-ALK+ cell line with high sensitivity to 
BGT226, and is suitable as a responder cell line.
Karpas299 cell line is mainly resistant  
to BgT226 in vitro
In contrast with SU-DHL-1 cells, Karpas299 cells did not 
respond to BGT226 in the low nanomolar range. In fact, 
about 10-fold higher concentrations of BGT226 as compared 
with SU-DHL-1 cells were necessary to observe inhibitory 
effects. MTT assay revealed an IC
50
 of about 100 nM that was 
independent of incubation time (Figure 2A). Accordingly, 
a relevant decrease of the S phase fraction and an increase of 
the G0/G1 fraction was only seen at the same high dose level 
using propidium iodide cell cycle analysis, whereas the subG1 
fraction indicating apoptosis was unaffected at any dose level 
or time point tested (Figure 2B). Consistent with viability 
and cell cycle assays, Western blot analysis revealed virtually 
unchanged Akt phosphorylation and incomplete inhibition of 
p70S6 kinase phosphorylation at 100 nM (Figure 2C). Thus, 
Karpas299 is an NPM-ALK+ cell line with low sensitivity to 
BGT226, and is suitable as a low/nonresponder cell line.
PeT imaging distinguishes BgT226-sensitive 
from BgT226-resistant lymphoma in vivo
Since SU-DHL-1 cells, but not Karpas299 cells, were sensi-
tive to BGT226, we evaluated whether PET imaging was able 
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Figure 1 sU-Dhl-1 is sensitive to phosphatidylinositol-3-kinase/mammalian target 
of rapamycin inhibition in vitro. 
Notes: (A) sU-Dhl-1 cells were cultured with BgT226 in the presence of increasing 
concentrations as indicated for 24 hours (left panel) and 48 hours (right panel). 
cell viability was assessed by MTT assay. (B) cell cycle distribution assessed by 
propidium iodide flow cytometry at 24 hours (left panel) and 48 hours (right panel). 
The bars represent the mean ± standard deviation of three individual experiments. 
(C) assessment of protein levels and target inhibition after 6 hours of incubation 
with BgT226 by immunoblotting using the indicated antibodies.
Abbreviation: MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
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to visualize therapeutic sensitivity and resistance, respec-
tively, early on in vivo. To this end, PET using the glucose 
analog FDG and the thymidine analog FLT as radiotracers 
was performed before and 7 days after initiation of treat-
ment with BGT226 in mice bearing either SU-DHL-1 or 
Karpas299 lymphoma xenografts.
SU-DHL-1 tumors treated with BGT226 showed a 
marked reduction in growth and only a modest increase in 
tumor volume until day 7 (n=10, mean 2.0-fold increase, 
standard deviation [SD] 0.22) followed by stabilization until 
day 14 (n=5; mean 2.1-fold increase, SD 0.20), whereas 
vehicle-treated control animals showed rapid growth of lym-
phomas on day 7 (n=7, mean 6.1-fold increase, SD 0.16) and 
day 14 (n=3; mean 11.6-fold increase, SD 0.17; P,0.001, 
Figure 3A). In contrast, Karpas299 cells gave rise to lym-
phomas that were mainly resistant to BGT226 (n=4, mean 
5.3-fold increase, SD 0.21) resulting in a tumor volume on 
day 14 similar to that of control tumors (n=4, mean 6.2-fold 
increase, SD 0.40; P=0.08, Figure 4A).
To test the suitability of PET imaging for very early 
response assessment, the TBR of both FLT-PET and FDG-
PET was determined before therapy and defined as 100%. 
A second PET scan was performed on day 7 of treatment, 
and change in TBR (ie, relative TBR) was calculated. In mice 
carrying SU-DHL-1 lymphoma, treatment with BGT226 led 
to a significant TBR reduction on day 7 for both FLT-PET 
(n=10, mean ± SD TBR 87%±20.8%, range 55%–119%, 
P=0.0007; Figure 3B) and FDG-PET (n=10, mean TBR 
81%±31.3%, range 35%–130%, P=0.0029; Figure 3C) 
compared with the control group (FLT, n=7, mean TBR 
152%±42.6%, range 100%–223%; FDG, n=7, mean TBR 
128%±17.4%, range 97%–153%). In contrast, PET imaging 
of resistant Karpas299 xenografts revealed no significant 
differences in relative TBR between the therapy and con-
trol groups for either FLT-PET (therapy, n=5, mean TBR 
127%±22.0%, range 100%–148%; control group, n=3, mean 
TBR 98%±21.1%, range 78%–120%, P=0.2; Figure 4B) or 
FDG-PET (therapy, n=4, mean TBR 130%±36.6%, range 
94%–162%; control group, n=4, mean TBR 116%±27.2%, 
range 91%–154%, P=0.6; Figure 4C). Thus, PET imaging 
with both tracers, FDG depicting tumor metabolism and 
FLT reflecting proliferation, were suitable for determining 
response as early as 7 days after initiation of treatment.
PeT results correlate with proliferation 
marker Ki67 in treated xenograft 
lymphomas
In order to determine the correlation between PET data and 
in vivo treatment effects, we performed immunohistochemical 
analysis on explanted tumors for the proliferation marker, Ki67, 
and the apoptosis marker, cleaved caspase-3. In SU-DHL-1 
lymphomas, treatment with BGT226 led to a small but sig-
nificant increase in apoptosis as quantified by cleaved caspase-
3-positive cells (n=4, mean 7.0%±5.3%) compared with 
untreated mice (n=4, mean 2.0%±1.4%; P=0.04, Figure 3D). 
Importantly, proliferation was substantially decreased by 
BGT226, with a mean of 14% Ki67-positive cells (n=5; SD 
7.5%) for the treated tumors and 64% (n=4; SD 20.3%) for the 
control tumors (P=0.002). In contrast, no significant changes 
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in apoptotic cells (therapy group, n=5, mean 1%, SD 0.8%; 
control group, n=3, mean 1%, SD 1.3%; P=0.7) or proliferat-
ing cells (therapy group, n=5, mean 44%, SD 18.2%; control 
group, n=3, mean 55%, SD 23.9%; P=0.5) could be observed 
in explanted Karpas299 xenografts (Figure 4D). Based on the 
strong concordance between tumor growth and response evalu-
ation by PET imaging in vivo as well as effective in vitro path-
way inhibition, our data suggest that both FLT- and  FDG-PET 
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are suitable for early differentiation between sensitive and 
refractory ALCL during BGT226 treatment.
Discussion
Constitutive activation of the PI3K/Akt/mTOR pathway 
occurs in many human cancers due to a variety of genetic 
aberrations leading to increased cell survival, growth and 
proliferation, protein synthesis and glucose metabolism, 
angiogenesis, and migration.4 Dual PI3K/mTOR inhibitors, 
eg, BEZ235 and BGT226, have shown antitumor activ-
ity in several preclinical solid and hematological tumor 
models.3,7,21–23 In addition, Phase I clinical trials are underway 
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7.5 mg/kg (n=9) or placebo (n=7) started when tumors reached a volume of approximately 300 mm3 (day 0). Mice received BgT226 or placebo for 4 consecutive days 
followed by a 3-day intermission after which therapy was resumed. Some mice were sacrificed on day 7 to explant lymphomas for immunohistochemical analysis (therapy 
group, n=5; control group, n=3) and the remaining animals were monitored for tumor growth until day 14. (A) Tumor growth measurements. in this setting, either FlT-PeT 
([B] therapy group, n=5; control, n=3) or FDg-PeT ([C] therapy group, n=4; control group, n=4) was performed on days 0 and 7. left: representative PeT scans showing 
change in tumor tracer uptake (arrows). Right: TBR was calculated and served as an indicator of tracer uptake. TBR on day 0 was defined as 100%. Change in TBR compared 
with pretreatment values is shown for treated (BgT226) and control animals. (D) immunohistochemistry of explanted lymphomas using the apoptosis marker, cleaved 
caspase-3, and the proliferation marker, Ki-67. Mean values ± standard deviation are shown. 
Abbreviations: PeT, positron emission tomography; FDg, 2-deoxy-2-[18F]fluoro-D-glucose; FLT, 3′-deoxy-3′-[18F]fluorothymidine; TBR, tumor-to-background ratio; pos, 
positive.
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to investigate safety and efficacy of PI3K/mTOR inhibitors, 
mainly in solid tumors.24–26 Various pharmacodynamic and 
predictive biomarkers have been incorporated in these stud-
ies to assess target inhibition, ie, biochemical assessment of 
tumor tissue and prediction of efficacy by imaging, eg, with 
FDG-PET. However, neither pathway downregulation22 nor 
metabolic response as assessed by FDG-PET24 necessarily 
correlate with clinical response. In contrast, early reduction 
of FLT uptake has been shown to be linked with in vivo 
sensitivity to PI3K/mTOR inhibition.22
In this study, two high-grade lymphoma cell lines rep-
resenting ALCL, ie, SU-DHL-1 and Karpas299, character-
ized by NPM-ALK-dependent PI3K/Akt/mTOR pathway 
activation,18 were used as cell line-based models to evaluate 
FDG-PET and FLT-PET as early response markers of com-
bined PI3K/mTOR inhibition using BGT226. We found that 
SU-DHL-1 cells, but not Karpas299 cells, were sensitive 
to BGT226 and that the TBRs of both FDG-PET and FLT-
PET were significantly reduced in mice bearing BGT226-
sensitive SU-DHL-1 xenografts compared with the control 
group, but not in BGT226-resistant Karpas299-induced 
lymphomas. Thus, PET imaging was able to discriminate 
between sensitive and resistant lymphoma and correlated 
with in vitro antitumor activity as well as immunohistochem-
istry of explanted lymphomas, revealing the antiproliferative 
and proapoptotic effects of BGT226 in vivo. In line with 
previous reports for other malignancies,21,23,27 treatment of 
sensitive ALCL cells (SU-DHL-1) with BGT226 in vitro 
resulted in a dose-dependent and to some extent time-
dependent decrease of cell viability in the low nanomolar 
range. Whereas mTORC1-dependent phosphorylation of 
S6K was completely abrogated with concentrations as low 
as 10 nM, PI3K-dependent phosphorylation of AKT was 
still present to a lower degree at 100 nM, suggesting that 
BGT226 suppresses mTORC1 activity more effectively than 
PI3K activity and that the release of the negative feedback 
loop exerted by p70S6K leading to Akt reactivation is not 
completely abolished. Similar observations have also been 
reported for BEZ235, another PI3K/mTOR inhibitor.22 The 
predominant mode of antiproliferative activity of BGT226 
in vitro was a dose-dependent shift of cells from the G2/M 
and S phase to the G0/G1 phase. The difference between 
SU-DHL-1 and Karpas299 cells with regard to susceptibil-
ity to BGT226 could therefore be explained by the different 
sensitivity of these cell lines to the antiproliferative effect 
of the cyclin-dependent kinase 1 inhibitor, p27kip1.28 A con-
siderable increase in apoptosis was only observed with high 
doses in a time-independent manner. The impact of BGT226 
on the cell cycle seems to differ markedly depending on the 
tumor model assessed, ranging from highly proapoptotic23 
to solely cytostatic effects.21,22
In vivo sensitivity to BGT226 correlated with the in vitro 
data and could be assessed noninvasively by both FDG-PET 
and FLT-PET on day 7. The observation that FLT-PET reflects 
the antiproliferative activity of inhibitors of the NPM-ALK/
PI3K/mTOR pathway early in the course of therapy has been 
reported for other lymphomas.18,29,30 In contrast with some 
of these studies, reduction of the TBR of FLT-PET seen in 
the present study was not that pronounced and moreover not 
significantly reduced when compared with the baseline TBR 
on day 0 in treated animals. Recent publications addressing 
the limitations of FLT-PET imaging have suggested that the 
mode of thymidine synthesis within the tumor cell could be 
a confounding factor in that the proliferative index of tumors 
driven by de novo thymidine synthesis is not adequately 
“lightened up” by FLT.31–33  However, it seems unlikely that 
predominant de novo thymidine synthesis under BGT226 
therapy contributes to the less marked reduction of FLT-PET 
given that we have already used both cell lines in a previous 
study18 without observing any limitations. However, inhibition 
of proliferation can be a transient phenomenon, especially 
when drugs are given on an intermittent basis, like BGT226 
in our study, ie, “4 days on, 3 days off ”. Western blot analysis 
of PI3K downstream targets after withdrawal of BGT226 
showed that its inhibitory effect was relieved as early as 16 
hours after the last dose.34 Thus, FLT-PET on day 7 after a 
72-hour drug-free interval might underestimate the long-term 
antiproliferative activity as tumor cells temporarily regain their 
proliferative capacity. Accordingly, an unexpected increase 
in FLT uptake has been seen in mantle cell lymphoma one 
week after single-shot mTOR inhibition.29 Taking pharmaco-
dynamic issues into account, we assume that FLT-PET would 
reflect an antiproliferative response more accurately when 
performed soon after drug administration.
Interestingly, FDG-PET also discriminated between sen-
sitive and resistant lymphoma. This was unexpected since 
many reports have demonstrated limitations of FDG-PET in 
monitoring response to targeted therapy,18,35,36 which has been 
attributed mainly to an influx of inflammatory cells resulting in 
increased FDG uptake.19,29 Of note, the PI3K/Akt/mTOR net-
work stimulates cellular glucose uptake via glucose transporter 
1 and phosphorylation to glucose-6-phosphate by hexokinase,4 
both representing the limiting steps in FDG uptake.37 It has 
therefore been proposed that reduction of FDG uptake dur-
ing PI3K/Akt and mTOR inhibition visualizes disruption of 
glucose metabolism rather than antiproliferative activity, given 
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that FDG-PET failed to predict the clinical response to the 
rapalog temsirolimus35 and BGT22624 in clinical studies. Still, 
FDG-PET and FLT-PET predicted the response to BGT226, 
suggesting equally strong concomitant inhibition of both pro-
liferation and glucose metabolism in our model of ALCL.
Conclusion
In summary, we have shown that the promising therapeutic 
efficacy of dual PI3K/mTOR inhibition can be monitored in 
an in vivo model of ALCL with either FDG-PET or FLT-PET 
early in the course of therapy. Our results should contribute 
to the design of preclinical and clinical studies incorporating 
PET imaging into pathway-directed treatments.
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